Analysis indicates that inflation in 2026 has risen compared to last year, primarily due to soaring energy and oil prices. Biotechnology company Vertex Pharmaceuticals holds a monopoly in cystic fibrosis treatment, giving it strong pricing power to offset rising costs. Financial services company Visa, with its transaction fees calculated as a percentage of the transaction amount, will see higher revenue per transaction as inflation drives up prices. In the third quarter of fiscal year 2026, Visa's revenue increased by 14% year-over-year to $11.6 billion, and adjusted earnings per share grew by 11% year-over-year to $3.32.